Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002
- Phase 1b study of AL002 enrolling Alzheimer’s disease patients will assess safety and pharmacodynamics, and will monitor target specific biomarkers
“We are excited that based on the safety profile in healthy volunteers observed to date, we can now advance to the Phase 1b portion of the study, evaluating AL002 in Alzheimer’s disease patients,” said
The Phase 1b portion of the INVOKE clinical study will assess the safety of multiple doses and measure target-specific biomarker changes related to AL002 in plasma and in cerebrospinal fluid (CSF) in Alzheimer’s disease patients.
“Based on strong genetic links between TREM2 and Alzheimer’s disease, we designed and developed AL002 to enhance TREM2 signaling and harness the immune system in the brain which we believe will address the multiple pathologies in Alzheimer’s disease,” said
AL002 is a monoclonal antibody that targets a triggering receptor expressed on myeloid cells 2 (TREM2) with the strongest genetic links after APOE4 to Alzheimer’s disease and other neurodegenerative disorders. TREM2 is a transmembrane receptor protein expressed on a subset of innate immune cells and selectively on microglia, which constitute the brain’s immune system. TREM2 is thought to promote improved cell migration to the site of injury, improved cell survival, increased phagocytosis, and increased cell proliferation. Loss of TREM2 function leads to Alzheimer's disease and other forms of dementia and research suggests that boosting TREM2 levels in the brain may prevent or reduce the severity of neurodegenerative disorders.
About Alzheimer’s Disease
Alzheimer’s disease is a degenerative brain disease and the most common form of dementia. It is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability of patients to care for themselves. In most people with Alzheimer’s symptoms first appear in their mid-60s. The Alzheimer’s Association estimates that as of 2018 there are 5.7 million Americans suffering from Alzheimer’s disease and project that number will rise to nearly 14 million by 2050.
About Collaboration with
Under the terms of the agreement,
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company’s plans for and anticipated benefits and mechanism of the Company’s product candidates, the timing and objectives of the clinical studies and anticipated regulatory and development milestones. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports
Source: Alector, Inc.